参考文献/References:
[1] Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults[J].JAMA,2013,310（9）：948-959.
[2] Mefford IN,Wade EU.Proton pump inhibitors as a treatment method for type Ⅱ diabetes[J]. Med Hypotheses,2009,73（1）：29-32.
[3] Boj-Carceller D,Playan-Uson J,Trincado-Aznar P,et al.Proton pump inhibitors for the treatment of diabetes mellitus?[J].Av Diabetol,2010,26（1）：45-46.
[4] Hove KD,F?覸rch K,B?觟dvarsdóttir TB,et al.Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients-a retrospective analysis[J].Diabetes Res Clin Pract,2010,90（3）： e72-e74.
[5] Boj-Carceller D,Bocos-Terraz P,Moreno-Vernis M,et al.Are proton pump inhibitors a new antidiabetic drug? A cross sectional study[J]. World J Diabetes,2011,2（12）：217-220.
[6] Crouch MA,Mefford IN,Wade EU.Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes[J]. J Am Board Fam Med,2012,25（1）：50-54.
[7] Mefford IN,Mefford JT,Burris CA.Improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration[J].Case Rep Endocrinol,2012,2012：468609.
[8] Hove KD,Br?覬ns C,F?覸rch K,et al.Effects of 12 weeks' treat-ment with a proton pump inhibitor on insulin secretion,glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes：a randomised double-blind prospective placebo-controlled study[J].Diabetologia, 2013,56（1）：22-30.
[9] B?觟dvarsdóttir TB,Hove KD,Gotfredsen CF,et al.Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus,a model of type 2 diabetes[J].Diabetologia, 2010,53（10）：2220-2223.
[10] Suarez-Pinzon WL,Yan Y,Power R,et al.Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice[J]. Diabetes,2005,54（9）： 2596-2601.
[11] Suarez-Pinzon WL,Lakey JR,Brand SJ,et al.Combination ther-apy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass[J].J Clin Endocrinol Metab,2005,90（6）： 3401-3409.
[12] Yoshihisa U,Susumu I,Yasuyuki M,et al.Effect of serum gastrin concentration on insulin resistance[J].Digest Absorp,2006,28（1）：42-45.
[13] Singh PK,Hota D,Dutta P,et al.Pantoprazole improves glycemic control in type 2 diabetes：a randomized,double-blind,placebo-controlled trial[J].J Clin Endocrinol Metab,2012,97（11）： E2105-E2108.
[14] Lim HC, Kim JH, Youn YH,et al.Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor：A prospective randomized, double-blind study[J]. J Neurogastroenterol Motil,2013,19（4）：495-502.
[15] Sanaka M,Yamamoto T,Kuyama Y.Effects of proton pump inhibitors on gastric emptying：a systematic review[J].Dig Dis Sci,2010,55（9）：2431-2440.
[16] Slama G,Balkau B,Valensi P. Comment on：Nathan DM,Buse JB,Davidson MB,et al. Management of hyperglycaemia in type 2 diabetes：a consensus algorithm for the initiation and adjust-ment of therapy.A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetologia 49：1711-1721.Diabetologia,2007,50（6）：1354-1355.
[17] Peters A.Incretin-based therapies： review of current clinical trial data[J].Am J Med,2010,123（3 Suppl）：S28-S37.
[18] Sumii M,Sumii K,Tari A,et al.Regulation of antral peptides by administration of omeprazole to healthy men[J]. Am J Gastroenterol,1994,89（11）：2033-2037.
[19] Katagiri F,Inoue S,Itoh H,et al.Omeprazole raises somatostatin and motilin in human plasma[J]. Biol Pharm Bull,2005,28（2）：370-373.
[2０] Theodoraki A,Khoo B,Hamda A,et al.Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome： pathophysiologic considerations[J]. Endocr Pract,2010,16（5）： 835-837.
[21] Resmini E,Minuto F,Colao A,et al.Secondary diabetes associ-ated with principal endocrinopathies：the impact of new treatment modalities[J]. Acta Diabetol,2009,46（2）：85-95.
相似文献/References:
[1]郑少雄.罗格列酮和心血管风险——近期文献解读[J].国际内分泌代谢杂志,2007,(04):231.
[2]凌厉,朱本章.胰岛素类似物安全性研究进展[J].国际内分泌代谢杂志,2007,(04):234.
[3]李颖,刘东方.餐后1小时血糖升高的意义及干预[J].国际内分泌代谢杂志,2007,(04):235.
[4]崔巍,施秉银.内质网应激介导β细胞生存/死亡的研究进展[J].国际内分泌代谢杂志,2007,(04):256.
[5]杨叶虹,胡仁明.SELDI-TOF-MS技术及其在糖尿病研究中的应用[J].国际内分泌代谢杂志,2007,(04):261.
[6]高妍.针对华人糖尿病特点优化降糖方案[J].国际内分泌代谢杂志,2007,(04):269.
[7]杨志霞,郭莹辉,杨永生,等.胰岛素泵和多次皮下注射治疗糖尿病的比较[J].国际内分泌代谢杂志,2007,(04):273.
[8]周建英,马向华.胃旁路术减肥同时改善糖代谢的机制[J].国际内分泌代谢杂志,2007,(04):285.
[9]李翠柳,朱大龙.破译肠道代谢信息,驱动治疗革新[J].国际内分泌代谢杂志,2014,(06):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
Li Cuiliu*,Zhu Dalong..Deciphering metabolic messages from the gut drives therapeutic innovation[J].International Journal of Endocrinology and Metabolism,2014,(02):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
[10]袁捷 姜云生 杜彦丽 王肃.1型糖尿病对小鼠早孕时期子宫肌层结构和细胞增殖的影响[J].国际内分泌代谢杂志,2015,(01):6.[doi:10.3760/cma.j.issn.1673-4157.2015.01.002]
Yuan JieJiang YunshengDu YanliWang Su.Effects of type 1 diabetes on the muscularis structure and cell proliferation of uterine in mice during early pregnancy[J].International Journal of Endocrinology and Metabolism,2015,(02):6.[doi:10.3760/cma.j.issn.1673-4157.2015.01.002]